Immunic Q3 2021 Earnings Report
Key Takeaways
Immunic reported its third quarter 2021 financial results, highlighting the advancement of its clinical programs, including IMU-838 and IMU-935. The company's cash and cash equivalents totaled $110.4 million as of September 30, 2021, which is expected to fund operations into 2023.
Fully enrolled Phase 2 CALDOSE-1 trial of IMU-838 in moderate-to-severe ulcerative colitis.
Initiated Phase 2 CALLIPER trial in progressive multiple sclerosis, intended to run concurrently with and to complement the Company’s Phase 3 ENSURE Program in relapsing multiple sclerosis.
Cash and cash equivalents totaled $110.4 million as of September 30, 2021, expected to fund Immunic into 2023.
Expecting top-line data from the phase 2 CALDOSE-1 trial in the first half of 2022.